MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- CIPLA - GLENMARK PHARMA
CIPLA vs GLENMARK PHARMA - Comparison Results
CIPLA Change
Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More
GLENMARK PHARMA 
Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More
Current Valuations
| CIPLA | GLENMARK PHARMA | CIPLA/ GLENMARK PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 37.1 | 15.2 | 245.0% | View Chart |
| P/BV | x | 4.3 | 2.5 | 173.1% | View Chart |
| Dividend Yield | % | 0.5 | 0.4 | 117.4% |
Financials
 CIPLA  GLENMARK PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| CIPLA Mar-20 |
GLENMARK PHARMA Mar-19 |
CIPLA/ GLENMARK PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 586 | 712 | 82.3% | |
| Low | Rs | 357 | 484 | 73.8% | |
| Sales per share (Unadj.) | Rs | 207.0 | 349.6 | 59.2% | |
| Earnings per share (Unadj.) | Rs | 18.6 | 32.8 | 56.7% | |
| Cash flow per share (Unadj.) | Rs | 33.2 | 44.3 | 74.8% | |
| Dividends per share (Unadj.) | Rs | 4.00 | 2.00 | 200.0% | |
| Dividend yield (eoy) | % | 0.8 | 0.3 | 253.7% | |
| Book value per share (Unadj.) | Rs | 195.5 | 198.6 | 98.4% | |
| Shares outstanding (eoy) | m | 806.35 | 282.17 | 285.8% | |
| Bonus/Rights/Conversions | ESOS | - | - | ||
| Price / Sales ratio | x | 2.3 | 1.7 | 133.1% | |
| Avg P/E ratio | x | 25.3 | 18.2 | 139.0% | |
| P/CF ratio (eoy) | x | 14.2 | 13.5 | 105.4% | |
| Price / Book Value ratio | x | 2.4 | 3.0 | 80.1% | |
| Dividend payout | % | 21.5 | 6.1 | 352.6% | |
| Avg Mkt Cap | Rs m | 379,912 | 168,625 | 225.3% | |
| No. of employees | `000 | 25.8 | 12.0 | 214.7% | |
| Total wages/salary | Rs m | 30,270 | 20,561 | 147.2% | |
| Avg. sales/employee | Rs Th | 6,459.6 | 8,196.0 | 78.8% | |
| Avg. wages/employee | Rs Th | 1,171.2 | 1,708.1 | 68.6% | |
| Avg. net profit/employee | Rs Th | 580.2 | 768.5 | 75.5% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 166,949 | 98,655 | 169.2% | |
| Other income | Rs m | 3,442 | 2,081 | 165.4% | |
| Total revenues | Rs m | 170,391 | 100,736 | 169.1% | |
| Gross profit | Rs m | 32,060 | 15,858 | 202.2% | |
| Depreciation | Rs m | 11,747 | 3,259 | 360.4% | |
| Interest | Rs m | 1,974 | 3,346 | 59.0% | |
| Profit before tax | Rs m | 21,782 | 11,335 | 192.2% | |
| Minority Interest | Rs m | -475 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 1,672 | 0.0% | |
| Tax | Rs m | 6,312 | 3,756 | 168.0% | |
| Profit after tax | Rs m | 14,995 | 9,250 | 162.1% | |
| Gross profit margin | % | 19.2 | 16.1 | 119.5% | |
| Effective tax rate | % | 29.0 | 33.1 | 87.4% | |
| Net profit margin | % | 9.0 | 9.4 | 95.8% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 117,038 | 66,968 | 174.8% | |
| Current liabilities | Rs m | 43,931 | 40,211 | 109.3% | |
| Net working cap to sales | % | 43.8 | 27.1 | 161.5% | |
| Current ratio | x | 2.7 | 1.7 | 160.0% | |
| Inventory Days | Days | 96 | 83 | 114.9% | |
| Debtors Days | Days | 85 | 81 | 104.8% | |
| Net fixed assets | Rs m | 107,424 | 33,322 | 322.4% | |
| Share capital | Rs m | 1,613 | 282 | 571.4% | |
| "Free" reserves | Rs m | 156,018 | 55,770 | 279.8% | |
| Net worth | Rs m | 157,630 | 56,052 | 281.2% | |
| Long term debt | Rs m | 23,693 | 35,738 | 66.3% | |
| Total assets | Rs m | 236,626 | 132,888 | 178.1% | |
| Interest coverage | x | 12.0 | 4.4 | 274.3% | |
| Debt to equity ratio | x | 0.2 | 0.6 | 23.6% | |
| Sales to assets ratio | x | 0.7 | 0.7 | 95.0% | |
| Return on assets | % | 7.2 | 9.5 | 75.7% | |
| Return on equity | % | 9.5 | 16.5 | 57.6% | |
| Return on capital | % | 12.8 | 17.8 | 72.1% | |
| Exports to sales | % | 33.0 | 0 | - | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | 55,175 | NA | - | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 56,036 | 62,998 | 88.9% | |
| Fx outflow | Rs m | 6,764 | 22,859 | 29.6% | |
| Net fx | Rs m | 49,272 | 40,140 | 122.8% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 30,685 | 13,242 | 231.7% | |
| From Investments | Rs m | 1,040 | -6,990 | -14.9% | |
| From Financial Activity | Rs m | -29,488 | -7,387 | 399.2% | |
| Net Cashflow | Rs m | 2,340 | -2,971 | -78.8% | |
Share Holding
| Indian Promoters | % | 16.0 | 48.3 | 33.1% | |
| Foreign collaborators | % | 20.8 | 0.0 | - | |
| Indian inst/Mut Fund | % | 12.2 | 6.9 | 176.8% | |
| FIIs | % | 23.7 | 34.4 | 68.9% | |
| ADR/GDR | % | 1.1 | 0.0 | - | |
| Free float | % | 26.2 | 10.5 | 249.5% | |
| Shareholders | 161,166 | 56,727 | 284.1% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare CIPLA With: WYETH PFIZER ALKEM LABORATORIES SHASUN PHARMA SANOFI INDIA
Compare CIPLA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Today's Market
Sensex Trades Over 500 Points Lower; Dow Futures Down by 77 Points(12:30 pm)
Share markets in India are presently trading on a negative note. The BSE Sensex is trading down by 553 points, down 1.1% at 47,794 levels.
Related Views on News
CIPLA 2019-20 Annual Report Analysis (Annual Result Update)
Nov 4, 2020 | Updated on Nov 4, 2020Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.
GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)
Sep 1, 2020 | Updated on Sep 1, 2020For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)
Aug 10, 2020 | Updated on Aug 10, 2020For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.
CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)
May 19, 2020 | Updated on May 19, 2020For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.
GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)
Feb 19, 2020 | Updated on Feb 19, 2020For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
More Views on NewsMost Popular
Time to Book Profits in Pharma Stocks(Fast Profits Daily)
Jan 15, 2021In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)
Jan 15, 2021The pandemic failed to thwart Richa's investing success formula for 2020.
One Chart to See Before You Sell(Fast Profits Daily)
Jan 22, 2021In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.
Invest in the Multibaggers of 2021 and Beyond(Profit Hunter)
Jan 21, 2021Our ace stock picker is ready to capitalise on a big growth opportunity.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2021
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
CIPLA SHARE PRICE
Jan 27, 2021 12:28 PM
TRACK CIPLA
- Track your investment in CIPLA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON CIPLA
CIPLA 5-YR ANALYSIS
COMPARE CIPLA WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Momentum Moves
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.